January 4, 2021

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion.

Exscientia, the world-leading artificial intelligence (AI) driven Pharmatech company, today announces the opening of its US based Miami office, with recruitment starting immediately.

Led by Chief Research Engineer, Adrian Schreyer, Exscientia are recruiting both AI Engineers and Cheminformaticians to join the new Miami office. Members of the team will have extensive opportunities to work in the globally important field of AI-driven drug design and be part of an interdisciplinary team of talented researchers based across the UK, US and Japan.

Current opportunities are on the Exscientia careers page (sub-headed Miami FL) https://www.exscientia.ai/careers and will be actively updated as further openings become available.

Commenting on the announcement, Andrew Hopkins, Exscientia's CEO said, "We're looking for talented individuals and are particularly interested to tap in to Miami's true potential as a leading technology hub. We believe Miami is an excellent location and a future leader in the AI space"

About Exscientia   

Exscientia is a global leading Pharmatech company, using Artificial Intelligence (AI) to drive drug discovery and is the first AI company to have designed a novel molecule to enter the clinic. Founded in 2012, Exscientia fuses the power of AI with the experience of seasoned drug hunters. Exscientia’s innovative Centaur Chemist® platform enables breakthrough productivity gains as well as new approaches to improve drug design. Novel compounds are automatically designed and prioritized for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development. 

Exscientia’s Centaur Biologist® platform drives the flexible analysis and prioritisation of discovery targets across all pharmaceutically relevant disease space. Exscientia is collaborating with several leading pharmaceutical and life sciences companies as well as building its own portfolio of innovative medicines. Exscientia has its headquarters in Oxford, England with further offices in Dundee, Scotland, the USA and Japan. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientialtd.  

Enquiries:  

Edelman PR:  
Anitra Sprauten; Edelman UK  
P: +44 (0)78 9685 9386  
Anitra.Sprauten@edelman.com  

Stephanie Crisp; Edelman UK  
P: +44 (0)75 8300 3417  
stephanie.crisp@edelman.com  

Exscientia:

Mark Swindells; Chief Commercial Officer
contact@exscientia.ai